AzTrials
AzTrials

Parkinson DiseaseNCT03463330

Benefits of Mild Body Exercises in Parkinson's Disease

A study testing Qigong exercise and Mild body exercise in people with Parkinson Disease, run by University of Kansas Medical Center at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to learn the effects of two mild body exercises on quality of life, non-motor symptoms, anxiety, depression, fatigue, sleep quality, cognition, and executive function on people with Parkinson's Disease (PD). Read more about this study

Who is it for?
Ages 45 to 70 years
Conditions the study is for
Parkinson Disease
What is being tested?
Qigong exercise and Mild body exercise
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
65 participants
Where
1 siteUnited States
Study dates
5 Jul 2017to Mar 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of idiopathic PD
  • Currently taking levodopa with some improvement in motor symptoms, and on a stable dose for a minimum of 4 weeks prior to starting the study
  • Hoehn \& Yahr stage I to III (mild to moderate PD)

Who cannot join

  • Mini Mental State Examination (MMSE) score < 24
  • Central neurological diseases other than PD or prior major head trauma with loss of consciousness, including other forms of parkinsonism, uncontrolled or significant cardiovascular diseases, orthopedic or medical problems that would interfere with gait
  • Being primarily wheelchair bound
  • Deep brain stimulation
  • Expected change in PD medications over the course of the study
  • Subjects with MRI contraindications such as pacemaker, aneurysm clips, artificial heart valves, metal fragments, foreign objects or claustrophobia.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Kansas Medical Center

    Kansas City, Kansas, 66160

Other trials in United States

About this study

The purpose of this study is to learn the effects of two mild body exercises on quality of life, non-motor symptoms, anxiety, depression, fatigue, sleep quality, cognition, and executive function on people with Parkinson's Disease (PD).

Being tested
Qigong exercise, Mild body exercise
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Qigong exerciseBehavioural

    The Qigong exercise is a series of mild exercise movements.

  • Mild body exerciseBehavioural

    Participants will be taught of series of similar movements to the Qigong exercise.

Study groups in NCT03463330
Study groupRoleWhat they receive
Intervention GroupExperimentalParticipation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
Receives: Behavioral: Qigong exercise
Control GroupSham comparatorParticipation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
Receives: Behavioral: Mild body exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Parkinson's Disease Sleep Scale (PDSS-2)

    This instrument has a total range of scores between 0 and 60. The lower the score the better.

    Measured: Change from Baseline to Week 12

Secondary outcomes (13)
  1. Parkinson's Disease Questionnaire (PDQ-39)

    Measure of quality of life. This instrument has a total range of scores between 0 and 156. The lower the score the better.

    Measured: Change from Baseline to Week 12

  2. Non Motor Symptom Questionnaire (NMSQuest)

    This instrument has a total range of scores between 0 and 30. The lower the score the better.

    Measured: Change from Baseline to Week 12

  3. Geriatric Anxiety Scale (GAS-10)

    This instrument has a total range of scores between 0 and 30. The lower the score the better.

    Measured: Change from Baseline to Week 12

  4. Geriatric Depression Scale (GDS-15)

    This instrument has a total range of scores between 0 and 15. The lower the score the better.

    Measured: Change from Baseline to Week 12

  5. Parkinson Fatigue Scale (PFS-16)

    This instrument has a total range of scores between 16 and 90. The lower the score the better.

    Measured: Change from Baseline to Week 12

  6. Parkinson's Disease-Cognitive Rating Scale (PD-CRS)

    This instrument has a total range of scores between 0 and 134. The higher the score the better.

    Measured: Change from Baseline to Week 12

  7. Frontal Assessment Battery (FAB-18)

    This instrument has a total range of scores between 0 and 18. The higher the score the better.

    Measured: Change from Baseline to Week 12

  8. Trail Making Test parts A

    This test examines the time required to complete a task of connecting numbers in ascending sequence.

    Measured: Change from Baseline to Week 12

  9. Trail Making Test parts B

    This test examines the required time for completing a task of connecting numbers and letters in ascending sequence.

    Measured: Change from Baseline to Week 12

  10. Unified Parkinson Disease Rating Scale (UPDRS)

    This instrument has a total range of scores between 0 and 199. The lower the score the better.

    Measured: Change from Baseline to Week 12

  11. IL-1beta

    Serum biomarker will be measured by Enzyme Linked Immuno-Sorbent Assay (ELISA).

    Measured: Change from Baseline to Week 12

  12. IL-6

    Serum biomarker will be measured by Enzyme Linked Immuno-Sorbent Assay (ELISA).

    Measured: Change from Baseline to Week 12

  13. TNF-alpha

    Serum biomarker will be measured by Enzyme Linked Immuno-Sorbent Assay (ELISA).

    Measured: Change from Baseline to Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2018
  2. Study start5 Jul 2017
  3. Primary completionFeb 2022 (estimated)
  4. Study completionMar 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Qigong exercise in intervention arm and mild body exercise in control arm
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
65 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03463330
Sponsor's protocol ID
STUDY00140835
Status last verified
Jan 2022
First submitted
6 Mar 2018
Last updated
21 Jan 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: We will share all IPD data that underlie results in our publications.

Publications

  • Moon S, Sarmento CVM, Colgrove Y, Liu W. Complementary Health Approaches for People With Parkinson Disease. Arch Phys Med Rehabil. 2020 Aug;101(8):1475-1477. doi: 10.1016/j.apmr.2020.03.024. Epub 2020 Jul 3. No abstract available.

    PubMed 32631594
  • Moon S, Sarmento CVM, Smirnova IV, Colgrove Y, Lyons KE, Lai SM, Liu W. Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson's Disease: A Protocol for a Randomized Controlled Trial. Medicines (Basel). 2019 Jan 18;6(1):13. doi: 10.3390/medicines6010013.

    PubMed 30669324
  • Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2024 Apr 8;4(4):CD013856. doi: 10.1002/14651858.CD013856.pub3.

    PubMed 38588457
  • Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Jan 5;1(1):CD013856. doi: 10.1002/14651858.CD013856.pub2.

    PubMed 36602886

Questions about this trial

What is this clinical trial studying?

A study testing Qigong exercise and Mild body exercise in people with Parkinson Disease, run by University of Kansas Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Parkinson's Disease Sleep Scale (PDSS-2) (time frame: Change from Baseline to Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03463330, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in